136

References

137

REFERENCES

1. Chicharro JL, Lucia A, Perez M, Vaquero AF, Urena R. “Saliva

composition and exercise”. Sports Med. 26, 1998, 17.

2. Manohara Reddy SA, Mudgal J, Bansal P, Vasanthraju SG,

Srinivasan KK, Rao CM, Gopalan Kutty N. “Antioxidant, anti-

inflammatory and anti-hyperglycaemic activities of heterocyclic

homoprostanoid derivatives”. Bioorg. Med. Chem. 19, 2011,384.

3. Frankmann SP. “A technique for repeated sampling of CSF from

the anesthetized rat”. Physiol. Behav. 37, 1986, 489.

4. Huestis MA, Cone EJ. Alternative testing matrices. In: Karch

SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press,

1998, 799–857.

5. Andes D, Stamsted T, Conklin R. “Pharmacodynamics of

amphotericin B in a neutropenic-mouse disseminated-

candidiasis model”. Antimicrob. Agents Chemother. 45, 2001,

922.

6. Caricato A, Pennisi M, Mancino A, Vigna G, Sandroni C,

Arcangeli C, Antonelli M. “Levels of vancomycin in the cerebral

interstitial fluid after severe head injury”. Intensive Care Med.

32, 2006, 325.

7. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Muddana

N, Saralaya R, Benade V. "A simple and rapid method to collect

the cerebrospinal fluid of rats and its application for the

138

assessment of drug penetration into the central nervous

system". J. Neurosci. Methods. 178, 2009, 116.

8. Chandra S. Chaurasia, Markus Müller, Edward D. Bashaw, Eva

Benfeldt,Jan Bolinder, Ross Bullock, Peter M. Bungay, Elizabeth

C.M. DeLange, Hartmut Derendorf, William F. Elmquist,

Margareta Hammarlund-Udenaes, Christian Joukhadar, Dean

L. Kellogg, Jr, Craig E. Lunte, Carl Henrik Nordstrom, Hans

Rollema, Ronald J. Sawchuk, Belinda W.Y. Cheung, Vinod P.

Shah, Lars Stahle, Urban Ungerstedt, Devin F. Welty, Helen

Yeo. “AAPS-FDA Workshop White Paper: Microdialysis

Principles, Application, and Regulatory Perspectives”. Report

From the Joint AAPS-FDA Workshop, November 4-5, 2005,

Nashville, TN. The AAPS Journal. 9, 2007, E48.

9. Chernet E, Martin LJ, Li D, Need AB, Barth VN, Rash KS,

Phebus LA. “Use of LC/MS to assess brain tracer distribution in

preclinical, in vivo receptor occupancy studies: Dopamine D2,

serotonin 2A and NK-1 receptors as examples”. Life Sci. 78,

2005, 340.

10. Idkaidek N, Arafat T. "Saliva versus Plasma Pharmacokinetics:

Theory and Application of a Salivary Excretion Classification

System". Mol. Pharm. 9, 2012, 2358.

11. Ruiz ME, Conforti P, Fagiolino P, Volonté MG. "The use of saliva

as a biological fluid in relative bioavailability studies:

139

comparison and correlation with plasma results". Biopharm.

Drug Dispos. 31, 2010, 476.

12. Smith JN, Wang J, Lin Y, Klohe EM, Timchalk C.

"Pharmacokinetics and Pharmacodynamics of Chlorpyrifos and

3,5,6-Trichloro-2-pyridinol (TCPy) in Rat Saliva After

Chlorpyrifos Administration". Toxicol. Sci. 2012.Aug 8 [Epub

ahead of print]

13. Fabritius M, Staub C, Mangin P, Giroud C. "Distribution of free

and conjugated cannabinoids in human bile samples". Forensic

Sci. Int. 2012, doi: 10.1016/j.forsciint.2012.08.013 [Epub

ahead of print]

14. Zhou L, Dockens RC, Liu-Kreyche P, Grossman SJ, Iyer RA. "In

vitro and in vivo metabolism and pharmacokinetics of BMS-

562086, a potent and orally bioavailable corticotropin-releasing

factor-1 receptor antagonist". Drug Metab. Dispos. 40, 2012,

1093.

15. Barnes AJ, Brunet BR, Choo RE, Mura P, Johnson RE, Jones

HE, Huestis MA."Excretion of methadone in sweat of pregnant

women throughout gestation after controlled methadone

administration". Ther. Drug Monit. 32, 2010, 497.

16. Dear GJ, Beaumont C, Roberts A, Squillaci B, Thomas S, Nash

M, Fraser D. “Approaches for the rapid identification of drug

metabolites in early clinical studies”. Bioanalysis. 3, 2011, 197.

140

17. Dhaneshwar SS, Gairola N, Kandpal M, Vadnerkar G, Bhatt L,

Rathi B, Kadam SS. “Synthesis, kinetic studies and

pharmacological evaluation of mutual azo prodrugs of 5-

aminosalicylic acid for colon-specific drug delivery in

inflammatory bowel disease”. Eur. J. Med. Chem. 44, 2009,

3922.

18. Bhatta RS, Chandasana H, Rathi C, Kumar D, Chhonker YS,

Jain GK. “Bioanalytical method development and validation of

natamycin in rabbit tears and its application to ocular

pharmacokinetic studies”. J. Pharm. Biomed. Anal. 54, 2011,

1096.

19. Prasanthi S, Vidyavathi M, Prasad KV, Krishna DR. “O-

demethylation of dextromethorphan using microbial

cultures”.Drug. Metab. Lett. 3, 2009, 10.

20. Matsu DM. "Therapeutic drug monitoring in pregnancy". Ther.

Drug Moni. 34, 2012, 207.

21. Nechuta S, Mudd LM, Elliott MR, Lepkowski JM, Paneth N;

“Michigan Alliance for the National Children's Study. Attitudes

of pregnant women towards collection of biological specimens

during pregnancy and at birth”. Paediatr. Perinat. Epidemiol. 26,

2012, 272.

22. Concheiro M, Jones HE, Johnson RE, Choo R, Huestis MA.

"Preliminary buprenorphine sublingual tablet pharmacokinetic

141

data in plasma, oral fluid, and sweat during treatment of opioid-

dependent pregnant women". Ther. Drug Monit. 33, 2011,619.

23. Kidwell DA, Holland JC, Athanaselis S. “Testing for drugs of

abuse in saliva and sweat”. J. Chromatogr. B. Biomed. Sci. Appl.

713, 1998, 111.

24. Atkinson HC, Begg EJ, Darlow BA. "Drugs in human milk.

Clinical pharmacokinetic considerations". Clin.

Pharmacokinet.14, 1988, 217.

25. Fortinguerra F, Clavenna A, Bonati M. "Psychotropic drug use

during breastfeeding: a review of the evidence". Pediatrics. 124,

2009, 547.

26. Halstead AC, Godolphin W, Lockitch G, et al. “Timing of

specimen collection is crucial in urine screening of drug

dependent mothers and newborns”. Clin. Biochem. 21, 1988,

59.

27. Graham K, Koren G, Klein J, et al. “Determination of gestational

cocaine exposure by hair analysis”. JAMA.262, 1989, 3328.

28. Vähäkangas K, Myllynen P. "Drug transporters in the human

blood-placental barrier". Br. J. Pharmacol. 158, 2009, 665.

29. Brown SD, Bartlett MG, White CA. "Pharmacokinetics of

intravenous acyclovir, zidovudine, and acyclovir-zidovudine in

pregnant rats". Antimicrob. Agents Chemother.47, 2003, 991.

142

30. Nirogi R, Bhyrapuneni G, Kandikere V, Muddana N, Saralaya R,

Komarneni P, Mudigonda K, Mukkanti K."Pharmacokinetic

profiling of efavirenz-emtricitabine-tenofovir fixed dose

combination in pregnant and non-pregnant rats". Biopharm.

Drug Dispos. 33, 2012, 265.

31. Montgomery D, Plate C, Alder SC, Jones M, Jones J,

Christensen RD. "Testing for fetal exposure to illicit drugs using

umbilical cord tissue vs meconium". J. Perinatol. 26, 2006, 11.

32. Stolk LM. "Meconium as a matrix". Clin. Pharmacokinet. 31,

1996, 81.

33. Gareri J, Klein J, Koren G."Drugs of abuse testing in

meconium". Clin. Chim. Acta. 366, 2006, 101.

34. Nageswara Rao R, Guruprasad K, Gangu Naidu Ch, Raju B,

Srinivas R.”LC-ESI-MS/MS determination of in vivo metabolites

of almotriptan in rat plasma, urine and feces: application to

pharmacokinetics”. J Chromatogr B Analyt Technol Biomed Life

Sci.891-892,2012,44.

35. Marchei E, Papaseit E, Garcia-Algar OQ, Farrè M, Pacifici R,

Pichini S. "Determination of atomoxetine and its metabolites in

conventional and non-conventional biological matrices by

liquid chromatography-tandem mass spectrometry". J Pharm

Biomed Anal. 60, 2012, 26.

143

36. Kielbasa W, Kalvass JC, Stratford R."Microdialysis evaluation of

atomoxetine brain penetration and central nervous system

pharmacokinetics in rats". Drug Metab Dispos. 37,2009, 137.

37. Mattiuz EL, Ponsler GD, Barbuch RJ, Wood PG, Mullen JH,

Shugert RL, Li Q, Wheeler WJ, Kuo F, Conrad PC, Sauer JM.

"Disposition and metabolic fate of atomoxetine hydrochloride:

pharmacokinetics, metabolism, and excretion in the Fischer 344

rat and beagle dog". Drug Metab Dispos. 2003 Jan;31(1):88-97.

38. Korth-Bradley JM, Parks V, Chalon S, Gourley I, Matschke K,

Gossart S, Bryson P, Fleckenstein L. "Excretion of moxidectin

into breast milk and pharmacokinetics in healthy lactating

women". Antimicrob Agents Chemother. 55, 2011, 5200.

39. Tabernero MJ, Felli ML, Bermejo AM, Chiarotti M.

"Determination of ketamine and amphetamines in hair by

LC/MS/MS". Anal Bioanal Chem. 395, 2009, 2547.

40. Gray TR, Shakleya DM, Huestis MA."A liquid chromatography

tandem mass spectrometry method for the simultaneous

quantification of 20 drugs of abuse and metabolites in human

meconium". Anal Bioanal Chem. 393, 2009, 1977.

41. Simon V, Ho DD. “HIV/AIDS epidemiology, pathogenesis,

prevention, and treatment”. Lancet. 368 (9534), 2006, 489.

42. Molina JM. “Efficacy and safety of once-daily regimens in the

treatment of HIV infection”. Drugs 68, 2008, 567.

144

43. Satyanarayana K, Srivastava S. “Universal access to HIV/AIDS

treatment: challenges ahead”. Indian J. Med. Res. 130 (6), 2009,

671.

44. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescent

45. Palella FJJ, Delane KM, Moorman AC, Aschman DJ, Holmberg

SD (1998). “Declining morbidity and mortality among patients

with advanced human immunodeficiency virus infection”. N.

Engl. J. Med. 338, 1998, 853.

46. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/0

21752s030lbl.pdf

47. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/

index.cfm? fuseaction=Search.DrugDetails

48. David W, Jason B, Zelalem T. “Antiretroviral Drugs”. J. Clin.

Pharmacol. 47, 2007, 1570.

49. Prabhakar K, Afzal SM, Kumar PU, Rajanna A, Kishan V. “Brain

delivery of transferrin coupled indinavir submicron lipid

emulsions--pharmacokinetics and tissue distribution”. Colloids

Surf. B Biointerfaces. 86, 2011, 305.

50. Kola I, Landis J. “Opinion: can the pharmaceutical industry

reduce attrition rates?”. Nat. Rev. Drug Discov. 3, 2004, 711.

51. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. “Drug

metabolism and pharmacokinetics, the blood-brain barrier, and

central nervous system drug discovery”. NeuroRx. 2, 2005, 554.

145

52. Pardridge WM. “Blood-brain barrier delivery”. Drug Discov.

Today 12, 2007, 54.

53. Fagerholm U. “The highly permeable blood-brain barrier: an

evaluation of current opinions about brain uptake capacity”.

Drug Discov Today. 12, 2007, 1076.

54. Kumar YS, Adukondalu D, Sathish D, Vishnu YV, Ramesh G,

Latha AB, Reddy PC, Sarangapani M, Rao YM. “P-Glycoprotein-

and cytochrome P-450-mediated herbal drug interactions”. Drug

Metabol. Drug Interact. 25, 2010:3.

55. Venishetty VK, Samala R, Komuravelli R, Kuncha M, Sistla R,

Diwan PV. β-Hydroxybutyric acid grafted solid lipid

nanoparticles: A novel strategy to improve drug delivery to

brain. Nanomedicine. 2012. doi: 10.1016/j.nano.2012.08.004.

56. Tovo PA, Newell ML, Mandelbrot L, Semprini A, Giaquinto C.

“Recommendations for the management of HIV infected women

and their infants”. A European Consensus. Luxembourg:

European Commission, 1999, 1.

57. Kind C, Rudin C, Siegrist CA.”Prevention of vertical HIV

transmission: additive protective effect of elective Cesarean

section and zidovudine prophylaxis”. AIDS. 12, 1998, 205.

58. Blattner W, Cooper E, Charurat M. “Effectiveness of potent

antiretroviral therapies on reducing perinatal transmission of

146

HIV-1”. XIII International Conference on AIDS. Durban. 2000,

[abstract LbOr4].

59. Lorenzi P, Spicher VM, Laubereau B. “Antiretroviral therapies

in pregnancy: maternal, fetal and neonatal effects”. AIDS. 12,

1998, F241.

60. Thorne C. “For the European Collaborative Study.

“Antiretroviral therapy and caesarean section to reduce vertical

transmission of HIV in Europe”. XIII International Conference

on AIDS, Durban, 2000, abstract (MoOrC240).

61. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin

A, Goebel FD, Phillips AN, Clotet B, Lundgren JD. “Virological

rebound after suppression on highly active antiretroviral

therapy”. AIDS 17, 2003, 1741.

62. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B,

Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli

P, Weber R. “Clinical progression and virological failure on

highly active antiretroviral therapy in HIV-1 patients: a

prospective cohort study. Swiss HIV Cohort Study”. Lancet. 353,

1999, 863.

63. Gedeon C, Koren G. “Designing Pregnancy Centered

Medications: Drugs Which Do Not Cross the Human Placenta”.

Placenta. 27, 2005; 1.

147

64. Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K,

Komarneni P, Aleti R, Mukkanti K. “Simultaneous

quantification of a non-nucleoside reverse transcriptase

inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor

emtricitabine and a nucleotide reverse transcriptase inhibitor

tenofovir in plasma by liquid chromatography positive ion

electrospray tandem mass spectrometry”. Biomed. Chromatogr.

23, 2009, 371.

65. Blum MR, Chittick GE, Begley JA, Zong J. “Steady-state

pharmacokinetics of emtricitabine and tenofovir disoproxil

fumarate administered alone and in combination in healthy

volunteers”. J. Clin. Pharmacol. 47, 2007, 751.

66. Ramanathan G, Shen G, Cheng A, Kearney BP.

“Pharmacokinetics of emtricitabine, tenofovir, and GS-9137

following coadministration of emtricitabine/tenofovir disoproxil

fumarate and ritonavir-boosted GS-9137”. J. Acquir. Immune.

Defic. Syndr. 45, 2007, 274.

67. Cao J, Huang L, Liu Y, Hoffman T, Stieger B, Meier PJ, Vore M.

“Differential regulation of hepatic bile salt and organic anion

transporters in pregnant and postpartum rats and the role of

prolactin”. Hepatology. 33, 2001, 140.

68. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D.

“ATP-dependent transport of glutathione S-conjugates by the

148

multidrug resistance-associated protein”. Cancer Res. 54. 1994,

4833.

69. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, and

Keppler D. “Transport of glutathione, glucuronate, and sulfate

conjugates by the MRP gene-encoded conjugate export pump”.

Cancer Res. 56, 1996, 988.

70. Keppler D, Konig J. “Hepatic canalicular membrane 5:

expression and localization of the conjugate export pump

encoded by the MRP2 (cMRP/cMOAT) gene in liver”. FASEB. J.

11, 1997, 509.

71. Suzuki H, Sugiyama Y. “Excretion of GSSG and glutathione

conjugates mediated by MRP1 and cMOAT/MRP2". Semin. Liver

Dis. 18, 1998, 359.

72. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli

WE. “Inhibition of MRP1/ABCC1, MRP2/ABCC2, and

MRP3/ABCC3 by Nucleoside, Nucleotide and Non-Nucleoside

Reverse Transcriptase Inhibitors”. Drug Metab. Dispos. 35,

2007, 340.

73. Foster C, Lyall H, Olmscheid B, Pearce G, Zhang S, Gibb DM.

“Tenofovir disoproxil fumarate in pregnancy and prevention of

mother-to-child transmission of HIV-1: Is it time to move on

from zidovudine”. HIV Med. 10(7), 2009,397.

149

74. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB.

“Fetal and maternal outcome after administration of Tenofovir to

gravid Rhesus Monkeys (Macaca mulatta)”. J. Acquir. Immune.

Defic Syndr. 29, 2002, 207.

75. Hutson JR, Koren G, Matthews SG. “Placental P-glycoprotein

and breast cancer resistance protein: Influence of

polymorphisms on fetal drug exposure and physiology”.

Placenta. 31, 2010, 351.

76. Macfarland A, Abramovich DR, Ewen SW, Pearson CK. “Stage-

specific distribution of P-glycoprotein in first-trimester and full-

term human placenta”. Histochem. J. 26, 1994, 417.

77. Meyer ZU Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch

S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. “Variable

expression of MRP2 (ABCC2) in human placenta: Influence of

gestational age and cellular differentiation”. Drug Metab. Dispos.

33, 2005, 896.

78. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M,

Lauper U, Meier PJ, Marin JJ. “Expression of members of

multidrug resistance protein family in human term placenta”.

Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, 2007, R1495.

79. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K,

Sugiyama Y. “Functional involvement of multidrug resistance-

associated protein 4 (MRP4/ABCC4) in the renal elimination of

150

the antiviral drugs adefovir and tenofovir”. Mol. Pharmacol. 71,

2007, 619.

80. Ray AS, Cihlar T, Robinson KL, Tong L, Vela JE, Fuller MD,

Wieman LM, Eisenberg EJ, Rhodes GR. “Mechanism of active

renal tubular efflux of tenofovir”. Antimicrob. Agents Chemother.

50, 2006, 3297.

81. Cheer SM and Wagstuff AJ. “Quetiapine: a review of its use in

the management of schizophrenia”. CNS Drugs. 18, 2004, 173.

82. Seroquel;http://www.astrazeneca.com/productbrowse/4_77.as

p, dated January 10, 2008.

83. Bezchlibnyk-Butler KZ and Jeffries JJ. “Clinical Handbook of

Psychotropic Drugs”. Hogrefe & Huber Publishers, Toronto,

1999.

84. Kapur S, Wadenberg ML, and Remington G. “Are animal studies

of antipsychotics appropriately dosed? Lessons from the bedside

to the bench”. Can. J. Psychiatry. 45, 2000, 241.

85. Ereshefsky L. “Pharmacokinetics and drug interactions:

updated for new antipsychotics”. Journal of clinical Psychiatry.

57, 1996, 12.

86. Goren JL and Levin GM. “Quetiapine and atypical

antipsychotic”. Pharmacotherapy. 18, 1998, 1183.

151

87. Markowitz JS, Brown CS, Moore TR. “Part 1: Pharmacology,

pharmacokinetics and efficacy”. The Annals of Pharmacotherphy

.33, 1999, 73.

88. Paxinos G and Watson C. “Rat brain in stereotaxic coordinates”.

Academic Press, New York, 2004.

89. Nirogi R, Bhyrapuneni G, Kandikere V, Mudigonda K, Ajjala D,

Mukkanti K. “Sensitive liquid chromatography tandem mass

spectrometry method for the quantification of Quetiapine in

plasma”. Biomedical Chromatography. 22, 2008, 1043.

90. Davis PC, Wong J and Gefvert O. “Analysis and

pharmacokinetics of quetiapine and two metabolites in human

plasma using reversed phase HPLC with ultraviolet and

electrochemical detection”. Journal of Pharmaceutical and

Biomedical Analysis. 20, 1999, 271.

91. Hasselstrom J and Linnet K. “Fully automated online

quantification of quetiapine in human serum by solid phase

extraction and liquid chromatography”. Journal of

Chromatography B. 798, 2003, 9.

92. Mandrioli R, Fanali S, Ferranti A and Raggi MA. “HPLC analysis

of the novel antipsychotic drug quetiapine in human plasma”.

Journal of Pharmaceutical and Biomedical Analysis. 30, 2002,

969.

152

93. Mercolini L, Grillo M, Bartoletti C, Boncompagni G and Raggi

MA. “Simultaneous analysis of classical neuroleptics, atypical

antipsychotics and their metabolites in human plasma”.

Analytical Bioanalytical Chemistry. 388, 2007, 235.

94. Sachse J, Koller J, Hartter S and Hiemke C. “Automated

analysis of quetiapine and other antipsychotic drugs in human

blood by high performance liquid chromatography with column-

switching and spectrophotometric detection”. Journal of

Chromatography B. 830, 2006, 342.

95. Saracino MA, Mercolini L, Flotta G, Albers LJ, Merli R and Raggi

MA. “Simultaneous determination of fluvoxamine isomers and

quetiapine in human plasma by means of high-performance

liquid chromatography”. Journal of Chromatography B. 843,

2006, 227.

96. Fisher DS, Handley SA, Taylor D, Flanagan RJ. "Measurement

of quetiapine and four quetiapine metabolites in human plasma

by LC-MS/MS". Biomed. Chromatogr. 26, 2012, 1125.

97. Davis PC, Bravo O, Gehrke M, Azumaya CT. "Development and

validation of an LC-MS/MS method for the determination of

quetiapine and four related metabolites in human plasma". J.

Pharm. Biomed. Anal. 51, 2010, 1113.

98. Nuutinen JM, Ratilainen J, Rissanen K, Vainiotalo P. “Mass

spectrometric studies on small open-chain piperazine-

153

containing ligands and their transition metal complexes”.

Journal of Mass Spectrometry. 36, 2001, 902.

99. Matheson Anna J and Lamb Harriet M. “Quetiapine: A review of

its clinical potential in the management of psychotic symptoms

in parkinson’s disease”. CNS Drugs. 14, 2000, 157.

100. Edell WS, Tunis SL. “Antipsychotic treatment of behavioral and

psychological symptoms of dementia in geropsychiatric

inpatients”. Am. J. Geriatr. Psychiatry. 9, 2001, 289.

101. Madhusoodanan S, Brenner R, Cohen CI. “Role of atypical

antipsychotics in the treatment of psychosis and agitation

associated with dementia”. CNS Drugs. 12, 1999, 135.

102. Grutzendler J, Morris C. “Cholinesterase inhibitors for

Alzheimer’s disease”. Drugs. 61, 2001, 41.

103. Seltzer B. “Donepezil: an update”. Expert Opin. Pharmacother. 8,

2007, 1011.

104. Reynolds PL, Strayer SM. “Neuroleptics for behavioral symptoms

of dementia”. J. Fam. Pract. 49, 1999, 78.

105. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP,

Dautzenberg PL, Eriksson S, Lawlor BA. “A randomized trial of

risperidone, placebo and haloperidol for behavioral symptoms in

dementia”. Neurology. 53, 1999, 946.

154

106. Hsing-Cheng L, Shih-Ku L, Sing-Ming S. “Extrapyramidal side

effects due to drug combination of risperidone and donepezil”.

Psychiatry Clin. Neurosci. 56, 2002, 479.

107. Parsa MA, Poggi E, Barte L. “Treatment of dementia patients

with psychotic and behavioral symptoms with quetiapine and

donepezil”. Eur. Neuropsychopharmacol. 10, 2002, 302.

108. US Food and Drug Administration (2005) FDA public health

advisory- deaths with antipsychotics in elderly patients with

behavioural disturbances. FDA/ center for drug evaluation and

research.www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafet

yInformationforPatientsandProviders/DrugSafetyInformationfor

HealthcareProfessionals/PublicHealthAdvisors/UCMOS3171.ht

m. Accessed 30 November 2011.

109. US Food and Drug Administration (2008) Information for

healthcare professionals: conventional antipsychotics.

FDA/center for drug evaluation and research.

www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformat

ionforPatientsandProviders/UCM124830.htm. Accessed 30

November 2011.

110. Bauman W, Pinner G. “Use of atypical antipsychotic drugs in

old age psychiatry”. Adv. Psychiatr. Treat. 8, 2002, 49.

111. Carcenac D, Martin-Hunyadi C, Kiesmann M, Demuynck-Roegel

C, Alt M, Kuntzmann F. “Extra-pyramidal syndrome induced by

donepezil”. Presse. Med. 29, 2000, 992.

155

112. Bentu´e-Ferrer D, Tribut O, Polard E, Allain H. “Clinically

significant drug interactions with cholinesterase inhibitors: a

guide for neurologists”. CNS Drugs. 17, 2003, 947.

113. Arai M. “Parkinsonism onset in a patient concurrently using

tiapride and donepezil”. Intern. Med. 39, 2000, 863.

114. Magnuson TM, Keller BK, Burke WJ. “Extrapyramidal side

effects in a patient treated with risperidone plus donepezil”. Am.

J. Psychiatry. 155, 1998, 1458.

115. Katner S, Bymaster F, Davis R, Nomikos G, Kennedy J, Perry K.

“The combination of olanzapine and donepezil increases

extracellular concentrations of dopamine and acetylcholine in

rat prefrontal cortex”. Proceedings of the 11th International

Conference on In Vivo Methods. 2006, 475.

116. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. “Effect of donepezil

hydrochloride (E2020) on basal concentration of extracellular

acetylcholine in the hippocampus of rats”. Eur. J. Pharmacol.

380, 1999, 101.

117. Nirogi R, Bhyrapuneni G, Kandikere V, Benade V, Muddana N,

Saralaya R, Irappanavar S, Ponnamaneni R, Mukkanti K.

“Concurrent administration of atypical antipsychotics and

donepezil: drug interaction study in rats”. Eur. J. Drug Metab.

Pharmacokinet. 37, 2012, 155.

156

118. Matsui K, Mishima M, Nagai Y, Yuzuriha T, Yoshimura T.

“Absorption, distribution, metabolism, and excretion of

donepezil (Aricept) after a single oral administration to Rat”.

Drug Metab. Dispos. 27, 1999, 1406.

119. Sharif ZA. “Pharmacokinetics, metabolism, and drug-drug

interactions of atypical antipsychotics in special populations.

Primary care companion”. J. Clin. Psychiatry. 5, 2003, 22.

120. Graylands Hospital Drug Bulletin 14 (1) 2006

http://www.Watag.org.au/wapdc/docs/GDB%2014-

2%20July06.pdf. Accessed 30 Nov 2011.

121. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M,

Phebus LA.. “Comparison of rat dopamine D2 receptor

occupancy for a series of antipsychotic drugs measured using

radio labeled or nonlabeled raclopride tracer”. Life Sci. 78,

2006, 3007.

122. Need AB, McKinzie JH, Mitch CH, Statnick MA, Phebus LA. “In

vivo rat brain opioid receptor binding of LY255582 assessed

with a novel method using LC/MS/MS and the administration

of three tracers simultaneously”. Life Sci. 81, 2007, 1389.

123. Nirogi R, Kandikere V, Bhyrapuneni G, Muddana N, Saralaya R,

Ponnamaneni RK, Manoharan AK. “In vivo receptor occupancy

assay of histamine H3 receptor antagonist in rats using non-

radiolabeled tracer”. Journal of Pharmacological and Toxicological

Methods. 65, 2012, 115.

157

124. Nirogi R, Kandikere V, Bhyrapuneni G, Saralaya R, Muddana N,

Ajjala DR. “Rat thalamic α4β2 neuronal nicotinic acetylcholine

receptor occupancy assay using LC-MS/MS”. Journal of

Pharmacological and Toxicological Methods. 65, 2012, 136.

125. Dajas BF, Wonnacott S (2004). “Nicotinic acetylcholine receptors

and the regulation of neuronal signalling”. Trends Pharmacol

Sci. 6, 2004, 317.

126. Sihver W, Nordberg A, Langstrom B, Mukhin AG, Koren AO,

Kimes AS, London ED. “Development of ligands for in vivo

imaging of cerebral nicotinic receptors”. Behav Brain Res. 113,

2000, 43.

127. Thomsen MS, Hansen HH, Timmerman DB, Mikkelsen JD.

“Cognitive improvement by activation of alpha7 nicotinic

acetylcholine receptors:from animal models to human

pathophysiology”. Curr. Pharm. Des. 16, 2010, 323.

128. MacAllan DRE, Lunt GG, Wonnacott S, Swanson KL, Rapoport

H, Albuquerque EX. “Methyllycaconitine and -anatoxin a

differentiate between nicotinic receptors in vertebrate and

invertebrate nervous systems”. FEBS Lett. 226, 1988, 357.

129. Nambi-Aiyar V, Benn MH, Hanna T, Jacyno J, Roth SH, Wilkins

JL. “The principle toxin of Delphinium brownie (Rydb.) and its

mode of action”. Experientia. 35, 1979, 1367.

158

130. Palma E, Bertrand S, Binzoni T, Bertrand D. “Neuronal 7

receptor expressed in Xenopus oocytes presents five putative

binding sites for methyllycaconitine”. J. Physiol. 491, 1996,

151.

131. Ward, J. M., Cockroft, V. B., Lunt, G. G., Smillie, F. S., &

Wonnacott, S. “Methyllycaconitine: A selective probe for

neuronal bungarotoxin binding site”. FEBS Letters 270, 1990,

45.

132. Wonnacott S, Albuquerque EX, Bertrand D. “Methyllycaconitine:

a new probe that discriminates between nicotinic acetylcholine

receptor subclasses”. Methods Neurosci. 12, 1993, 263.

133. Davies ARL, Hardick DJ, Blagbrough IS, Potter BVL,

Wolstenholme AJ, Wonnacott S. “Characterization of the binding

of [3H] methyllycaconitine: a new radioligand for labeling a7-

type neuronal nicotinic acetylcholine receptors”.

Neuropsychopharmacol. 38, 1999, 679.

134. Donna LM, Geraldine H, Min D, uke D, Einstein E, Gurley D,

Gordon JC, Bock MJ, Smith JS, Bialecki R, Eisman M, Elmore

CS, Werkheiser JL. “Pre-clinical validation of a novel alpha-7

nicotinic receptor radiotracer, [3H] AZ11637326: Target

localization, biodistribution and ligand occupancy in the rat

brain”. Neuropharmacol. 61, 2011, 161.